Shares of Glenmark, Alembic, and Sun Pharma will be in focus after the USFDA flagged recalls over manufacturing lapses. Glenmark is recalling Carvedilol and Theophylline tablets due to nitrosamine impurities and failed dissolution tests, while Alembic pulled Doxepin capsules and Sun Pharma recalled Spironolactone tablets. All three were classified as Class II recalls, indicating moderate health risk.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets